Alzheimer’s Phospho-Tau 217 Test

The Alzheimer’s Phospho-Tau 217 (p-Tau217) Test is an advanced blood biomarker test used to detect early signs of Alzheimer's disease. It measures phosphorylated tau protein levels, helping identify neurodegeneration years before symptoms appear. Conducted in a UKAS-accredited laboratory, with optional GP consultation for interpretation. 

What is the Alzheimer’s Phospho-Tau 217 Test?

The Phospho-Tau 217 (p-Tau217) Test is one of the most advanced blood tests currently available for detecting early Alzheimer’s disease. It measures a specific form of tau protein — tau phosphorylated at position 217 — which becomes abnormally elevated when Alzheimer’s pathology develops in the brain.

In Alzheimer’s disease, tau proteins become misfolded and form neurofibrillary tangles, disrupting communication between neurons and leading to cognitive decline. Traditionally, diagnosing this process required PET scans or cerebrospinal fluid (CSF) analysis, both of which are expensive and invasive.

The p-Tau217 blood test offers a non-invasive alternative, with studies showing it has very high accuracy (often >85–90%) in detecting Alzheimer’s-related changes — even before noticeable memory loss occurs.

At London Blood Tests, this assay is performed using ultra-sensitive immunoassay technology, capable of detecting extremely low concentrations of phosphorylated tau in blood plasma.

Benefits of the Alzheimer’s Phospho-Tau 217 Test

1. Early detection of Alzheimer’s pathology
   p-Tau217 rises years before clinical symptoms, allowing identification of neurodegenerative changes at a stage when interventions may be most effective.
2. Non-invasive alternative to brain scans
   Replaces the need for PET imaging or lumbar puncture, making Alzheimer’s screening more accessible and less stressful for patients.
3. High diagnostic accuracy
   Strong correlation with amyloid plaques and tau tangles provides reliable insight into whether cognitive symptoms are due to Alzheimer’s rather than other conditions.
4. Differentiates Alzheimer’s from other dementias
   Helps distinguish Alzheimer’s disease from conditions like vascular dementia or frontotemporal dementia, improving diagnostic precision.
5. Supports proactive cognitive health planning
   Early knowledge allows patients to optimise lifestyle, diet, cardiovascular health, and cognitive training to potentially slow progression.
6. Useful for monitoring disease progression
   Changes in p-Tau217 levels over time can help clinicians track disease activity or response to treatment.
7. Optional GP consultation for interpretation
   Results can be reviewed with a GP, who may recommend further investigations such as MRI, cognitive testing, or neurology referral.

Why Do I Need a Phospho-Tau 217 Test?

You may consider this test if you:

• Have a family history of Alzheimer’s disease
• Experience memory issues, confusion, or cognitive decline
• Want early screening for neurodegenerative risk
• Have been diagnosed with mild cognitive impairment (MCI)
• Are undergoing longevity or preventive health assessment

Common symptoms prompting testing include:

• Forgetfulness affecting daily activities
• Difficulty concentrating or processing information
• Trouble finding words or following conversations
• Changes in mood, behaviour, or decision-making

Because Alzheimer’s develops slowly, early detection allows for better planning, intervention, and monitoring.

Step-by-Step: How the Test Works

In-Clinic Testing at London Blood Tests

1. Book Your Appointment
   • Schedule online or by phone — no referral required.
   • No fasting is typically required unless combined with other tests.
2. Pre-Test Review
   • Your clinician may review symptoms, family history, and medications to ensure appropriate testing.
3. Sample Collection
   • A venous blood sample is collected by a trained phlebotomist.
   • The process takes approximately 5–10 minutes.
4. Laboratory Analysis
   • Your sample is sent to a specialist UKAS-accredited neurobiomarker laboratory.
   • p-Tau217 levels are measured using ultra-sensitive immunoassay platforms (e.g., SIMOA technology).
5. Quality Control
   • Results are validated with strict calibration and internal controls to ensure precision at very low biomarker levels.
6. Results Delivery
   • Results are typically available within 10–14 business days.
   • You’ll receive a detailed report with interpretation ranges.
7. Optional GP Consultation
   • A GP can explain your results and recommend next steps such as neurology referral, imaging, or cognitive testing.

At-Home Blood Draw (Home or Hotel Service)

1. Book Your Visit
   • Schedule a home or hotel phlebotomy appointment at your convenience.
2. Phlebotomist Visit
   • A qualified professional visits your location to collect a venous blood sample safely and discreetly.
3. Sample Transport
   • The sample is securely packaged and couriered to a UKAS-accredited lab under controlled conditions.
4. Advanced Biomarker Testing
   • The laboratory measures p-Tau217 levels using high-sensitivity detection platforms.
5. Results Delivery
   • Results are released within 10–14 business days via secure online access.
6. Optional GP Consultation
   • Book a consultation to interpret results and plan further investigations if necessary

Your Phospho-Tau 217 Results – Explained

Results are typically reported as concentration levels (pg/mL):

• Low / Normal Levels:
  Suggest no significant Alzheimer’s-related tau pathology detected.
• Elevated Levels:
  Indicate tau accumulation in the brain, strongly associated with Alzheimer’s disease.
• Borderline / Intermediate:
  May require repeat testing, imaging (MRI/PET), or additional biomarkers (e.g., amyloid beta or p-Tau181).

Clinical Interpretation Notes:

• p-Tau217 correlates strongly with amyloid plaque burden and tau tangles
• Elevated levels may appear 10–20 years before symptoms
• Results should always be interpreted alongside clinical symptoms and cognitive assessments